Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization

doi:10.1111/hel.12916

Editorial

. 2022 Oct;27(5):e12916.

doi: 10.1111/hel.12916. Epub 2022 Aug 8.

Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization

Zishao Zhong^{1

2}, Bingjie Zhan³, Baohui Xu³, Hengjun Gao^{1

3}

Affiliations

¹ Tongji Hospital, Institute of Digestive Disease, School of Medicine, Tongji University, Shanghai, China.
² The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
³ China Center for Helicobacter pylori Molecular Medicine, Shanghai, China.

PMID: 35939537
DOI: 10.1111/hel.12916

Editorial

Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization

Zishao Zhong et al. Helicobacter. 2022 Oct.

. 2022 Oct;27(5):e12916.

doi: 10.1111/hel.12916. Epub 2022 Aug 8.

Authors

Zishao Zhong^{1

2}, Bingjie Zhan³, Baohui Xu³, Hengjun Gao^{1

3}

Affiliations

¹ Tongji Hospital, Institute of Digestive Disease, School of Medicine, Tongji University, Shanghai, China.
² The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
³ China Center for Helicobacter pylori Molecular Medicine, Shanghai, China.

PMID: 35939537
DOI: 10.1111/hel.12916

No abstract available

Keywords: Helicobacter pylori; eradication on primary treatment; personalized treatment; standardized treatment.

PubMed Disclaimer

Comment on

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Tacconelli E, et al. Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21. Lancet Infect Dis. 2018. PMID: 29276051

Cited by

Prevalence of Helicobacter pylori Infection and Efficacy of Bismuth Quadruple and Levofloxacin Triple Eradication Therapies: A Retrospective Analysis.
Serena P, Popa A, Bende R, Miutescu B, Mare R, Borlea A, Aragona G, Groza AL, Serena L, Popescu A, Sporea I, Sirli R. Serena P, et al. Life (Basel). 2024 Jul 17;14(7):885. doi: 10.3390/life14070885. Life (Basel). 2024. PMID: 39063638 Free PMC article.
Effect of an individualized bismuth quadruple regimen guided by 10-day or 14-day antibiotic susceptibility testing for first-line eradication treatment of Helicobacter pylori in Ningxia, China.
Su X, Deng Y, Chen X, Li Y, Hao Q, Tang Y, Mu R, Wu Y, Zhou Y, Hu S. Su X, et al. Front Med (Lausanne). 2025 Jan 10;11:1510376. doi: 10.3389/fmed.2024.1510376. eCollection 2024. Front Med (Lausanne). 2025. PMID: 39867921 Free PMC article.

References

REFERENCES

1. Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47:868-876.
1. Sugano K, Tack J, Kuipers EJ, et al. Faculty members of Kyoto global consensus conference. Kyoto global consensus report on helicobacter pylori gastritis. Gut. 2015;64:1353-1367.
1. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.
1. Lee Y-C, Chiang T-H, Chou C-K, et al. Association between helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:1113-1124.e5.
1. Choi IJ, Kook M-C, Kim Y-I, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378:1085-1095.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

[1] Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47:868-876.

[2] Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47:868-876.

[3] Sugano K, Tack J, Kuipers EJ, et al. Faculty members of Kyoto global consensus conference. Kyoto global consensus report on helicobacter pylori gastritis. Gut. 2015;64:1353-1367.

[4] Sugano K, Tack J, Kuipers EJ, et al. Faculty members of Kyoto global consensus conference. Kyoto global consensus report on helicobacter pylori gastritis. Gut. 2015;64:1353-1367.

[5] Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.

[6] Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.

[7] Lee Y-C, Chiang T-H, Chou C-K, et al. Association between helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:1113-1124.e5.

[8] Lee Y-C, Chiang T-H, Chou C-K, et al. Association between helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:1113-1124.e5.

[9] Choi IJ, Kook M-C, Kim Y-I, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378:1085-1095.

[10] Choi IJ, Kook M-C, Kim Y-I, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378:1085-1095.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization

Affiliations

Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization

Authors

Affiliations

Comment on

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical